The novel MEK1/2 inhibitor AZD6244 (ARRY-142886) inhibits the growth of melanomas harboring the BRAF V600E mutation in vitro and in vivo

被引：0
|
作者：
Haass, N. K. [1 ]
Smalley, K. S. [1 ]
Sproesser, K. [1 ]
Contractor, R. [1 ]
Herlyn, M. [1 ]
机构：
[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2007年 / 127卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
931
引用
收藏
页码：S156 / S156
页数：1
相关论文
共 50 条
  • [41] A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer
    Dustin A. Deming
    Ludmila L. Cavalcante
    Sam J. Lubner
    Daniel L. Mulkerin
    Noelle K. LoConte
    Jens C. Eickhoff
    Jill M. Kolesar
    Suzanne Fioravanti
    Tim F. Greten
    Kathryn Compton
    Austin G. Doyle
    George Wilding
    Austin Duffy
    Glenn Liu
    Investigational New Drugs, 2016, 34 : 168 - 175
  • [42] A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer
    Deming, Dustin A.
    Cavalcante, Ludmila L.
    Lubner, Sam J.
    Mulkerin, Daniel L.
    LoConte, Noelle K.
    Eickhoff, Jens C.
    Kolesar, Jill M.
    Fioravanti, Suzanne
    Greten, Tim F.
    Compton, Kathryn
    Doyle, Austin G.
    Wilding, George
    Duffy, Austin
    Liu, Glenn
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 168 - 175
  • [43] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Adjei, Alex A.
    Cohen, Roger B.
    Franklin, Wilbur
    Morris, Clive
    Wilson, David
    Molina, Julian R.
    Hanson, Lorelei J.
    Gore, Lia
    Chow, Laura
    Leong, Stephen
    Maloney, Lara
    Gordon, Gilad
    Simmons, Heidi
    Marlow, Allison
    Litwiler, Kevin
    Brown, Suzy
    Poch, Gregory
    Kane, Katie
    Haney, Jerry
    Eckhardt, S. Gail
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2139 - 2146
  • [44] RETRACTION: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib (Retraction of Vol 24, Pg 3002, 2018)
    Song, Hao
    Zhang, Jinna
    Ning, Liang
    Zhang, Honglai
    Chen, Dong
    Jiao, Xuelong
    Zhang, Kejun
    MEDICAL SCIENCE MONITOR, 2022, 28
  • [45] The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600E Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells
    Liu, Ruixin
    Liu, Dingxie
    Xing, Mingzhao
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (02): : E173 - E182
  • [46] AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
    Davies, Barry R.
    Logie, Armelle
    McKay, Jennifer S.
    Martin, Paul
    Steele, Samantha
    Jenkins, Richard
    Cockerill, Mark
    Cartlidge, Sue
    Smith, Paul D.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (08) : 2209 - 2219
  • [47] In vitro antiproliferative activity of natural product-based MEK1 inhibitor E6201 against V600E BRAF-mutated cancer cell lines
    Nomoto, Kenichi
    Wang, John
    Wu, Jiayi
    Agoulnik, Sergei
    Kuznetsov, Galina
    Towle, Murray
    Schnaderbeck, Matthew
    Gusovsky, Fabian
    Shirota, Hiroshi
    Littlefield, Bruce
    CANCER RESEARCH, 2009, 69
  • [48] Frequent Loss of PTEN and NM23H1 in Melanomas Harboring a BRAF V600E Mutation-Implications for Targeted Therapy
    Snow, A. N.
    Milhem, M. M.
    Bossler, A. D.
    Ma, D.
    MODERN PATHOLOGY, 2013, 26 : 446A - 446A
  • [49] Frequent Loss of PTEN and NM23H1 in Melanomas Harboring a BRAF V600E Mutation-Implications for Targeted Therapy
    Snow, A. N.
    Milhem, M. M.
    Bossler, A. D.
    Ma, D.
    LABORATORY INVESTIGATION, 2013, 93 : 446A - 446A
  • [50] Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review
    Venkatesh, Ashwin
    Joshi, Amol
    Allinson, Kieren
    Das, Tilak
    Santarius, Thomas
    Jefferies, Sarah J.
    Harris, Fiona P.
    Jena, Rajesh
    Doherty, Gary J.
    CURRENT PROBLEMS IN CANCER, 2021, 45 (05)
12345